Acquired immunotherapy resistance in PDA (RNA-seq)
收藏NIAID Data Ecosystem2026-05-01 收录
官方服务：
资源简介：
36 samples were sequenced with duplicates or triplicates Overall design: RNA-seq
应用场景：
创建时间：
2024-03-07
相关数据集
DataSheet4_A systematic pan-cancer analysis reveals the clinical prognosis and immunotherapy value of C-X3-C motif ligand 1 (CX3CL1).ZIP
It is now widely known that C-X3-C motif ligand 1 (CX3CL1) plays an essential part in the process of regulating pro-inflammatory cells migration across a wide range of inflammatory disorders, includin
NIAID Data Ecosystem00
A microRNA-regulated transcriptional state defines intratumoral CD8+T cells that respond to immunotherapy. A microRNA-regulated transcriptional state defines intratumoral CD8+T cells that respond to immunotherapy
Rising rates of advanced-stage colorectal cancer (CRC) and poor survival rates necessitate effective therapeutic options. Immune checkpoint inhibition (ICI), specifically anti-PD-1 therapy, shows pote
NIAID Data Ecosystem00
Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)
This is a Phase 1/2, first-in-human, open-label, dose escalation and dose-expansion study of E-602, administered alone and in combination with cemiplimab.
NIAID Data Ecosystem10
Table 1_Improving CD3 bispecific antibody therapy in solid tumors using combination strategies.pdf
CD3 bispecific antibodies (bsAbs) are emerging as an important treatment option in the arsenal of oncologists. There are numerous FDA-approved CD3 bsAbs for both hematological and solid tumors. Despit
NIAID Data Ecosystem00
